Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond; n is 0–2; Q is cycloalkyl, optionally substituted by R13 and R14; R13 and R14 are independently selected from (C1–C6)alkyl, (C3–C8)cycloalkyl, —OH, (C1–C6)alkoxy, R27-aryl(C1–C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3–6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering
Type:
Grant
Filed:
April 14, 2003
Date of Patent:
December 4, 2007
Assignee:
Schering Corporation
Inventors:
Samuel Chackalamannil, William J. Greenlee, Yuguang Wang, Wenxue Wu, Enrico P. Veltri, Yan Xia
Abstract: A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders:
For example, a representative compound of the invention is:
Type:
Grant
Filed:
August 28, 2001
Date of Patent:
November 23, 2004
Assignee:
Schering Corporation
Inventors:
Samuel Chackalamannil, Yuguang Wang, Craig D. Boyle, Andrew W. Stamford